Pasireotide
Brand Names: Signifor, Signifor Lar
Methodology & AI Transparency ⓘ
Pasireotide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pasireotide is an FDA-registered prescription somatostatin analog (subcutaneous-route administration) manufactured/labeled by Recordati Rare Diseases, Inc.
- 2 Real-world patient consensus: Tracked across 6 patient dosage logs with a 90% satisfaction benchmark (RxCUI RXN-55292133-2664).
- 3 Typical cash cost range: 30-day cash pricing ranges from $70.06 discount cash to $171.65 walk-in retail (NADAC $1.5200/unit).
- 4 Top reported side effects / signs: Most commonly reported Pasireotide tolerability events: dizziness (6.2%), headache (6.5%), fatigue (5.9%).
Ask our AI Specialists anything about Pasireotide
Pasireotide Mechanism, CYP450 Pathways & DailyMed Monograph
Pasireotide is an FDA-registered prescription somatostatin analog (subcutaneous-route administration) manufactured/labeled by Recordati Rare Diseases, Inc. under National Drug Code 55292-133, 55292-140, supplied in .9 mg/mL Injection and Kit for physician-directed therapeutic management.
Pharmacologically, Pasireotide functions within the Somatostatin Analog class via subcutaneous-route delivery (.9 mg/mL Injection and Kit), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 55292-133, 55292-140 (manufactured/labeled by Recordati Rare Diseases, Inc.).
Pharmacokinetic profiling of Pasireotide demonstrates an elimination half-life of Terminal t½ estimated at 10–22 hrs depending on renal/hepatic reserve (Pasireotide) with Complete (~100%) parenteral systemic delivery for Pasireotide (.9 mg/mL Injection) systemic bioavailability; clearance proceeds via mixed metabolic conjugation and unchanged urinary excretion across pasireotide regimens, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after pasireotide administration.
Titration schedules for Pasireotide (.9 mg/mL Injection → Kit → .6 mg/mL Injection → .3 mg/mL Injection) require excluding severe drug-induced hypersensitivity to pasireotide or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-01 for pasireotide; real-world patient logs highlight headache (6.5% of reports), dizziness (6.2% of reports), fatigue (5.9% of reports) alongside a 90.00% Worth-It consensus.
Assess baseline hepatic panels and interacting prescriptions when starting Pasireotide (somatostatin analog).
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Pasireotide dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Pasireotide or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-01 for Pasireotide
Logged Side-Effect Incidence (6 Reports)
Pasireotide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pasireotide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of In an experimental setting, treatment with acarbose and pasireotide reduced PBH. Diabetes, obesity & metabolism • 2019-09-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 31144430 ↗ |
| Can This Approach Help? Inside the Latest Research on Management of high blood sugar associated with pasireotide (SOM230): healthy Vildagliptin and liraglutide were most effective in minimizing pasireotide-associated high blood sugar in healthy volunteers. Diabetes research and clinical practice • 2014-03-15 • Randomized Controlled Trial | N = 18 | 82/100 | PMID 24461109 ↗ |
Pasireotide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.5200/unit (~$45.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $171.65 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $70.06 / mo | View logs ↓ |
Pasireotide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Pasireotide RxNorm Concept ID | RXN-55292133-2664 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.5200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $171.65 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $70.06 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Pasireotide Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Pasireotide integrating DailyMed SPL (2026-07-01), CMS NADAC ($1.5200/unit), and 6 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Pasireotide community threads and patient logs by age, biological sex, dosage, and treatment duration.